Please login to the form below
Tobi Podhaler
This page shows the latest Tobi Podhaler news and features for those working in and with pharma, biotech and healthcare.
NICE backs Novartis/ ThromboGenics’ eye drug
ranibizumab). Novartis has also won the cost-effectiveness watchdog's backing in 2013 for the Tobi Podhaler (tobramycin), a treatment for cystic fibrosis.
Latest news
-
NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest
The limited recommendation takes into account that the Tobi Podhaler and Colobreathe are dry powder versions of already available nebulised products. ... form. The Tobi Podhaler should only be used in cystic fibrosis patients for whom nebulised
-
NICE backs two cystic fibrosis treatments for NHS use
Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price. Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS in England and Wales ... The final draft guidance from the
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- FDA approves Roche’s Actemra COVID-19 trial
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
